Akorn Receives Product Approval
November 26 2018 - 5:29PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, announced that it received a new
Abbreviated New Drug Application (ANDA) approval from the U.S. Food
and Drug Administration for diclofenac sodium topical gel,
1%. The product is manufactured at Akorn’s Amityville, New
York manufacturing facility.
According to IQVIA, the U.S. market for diclofenac sodium
topical gel, 1% was approximately $357 million for the twelve
months ended September 2018, with three current
competitors. The IQVIA market size is not a forecast of our
future sales.
Diclofenac sodium topical gel, 1% is indicated for the relief of
the pain of osteoarthritis of joints amenable to topical treatment,
such as the knees and those of the hands. Diclofenac sodium topical
gel, 1% has not been evaluated for use on the spine, hip, or
shoulder.
About AkornAkorn, Inc. is a specialty generic
pharmaceutical company engaged in the development, manufacture and
marketing of multisource and branded pharmaceuticals. Akorn has
manufacturing facilities located in Decatur, Illinois; Somerset,
New Jersey; Amityville, New York; Hettlingen, Switzerland and
Paonta Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024